相关实验视频
Updated: Jul 2, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Capivasertib:首次获得批准
1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.
卡维萨塞蒂布 (TruqapTM) 是一种新型的癌症治疗方法,已获批准用于HR阳性,HER2阴性乳腺癌. 这种泛-AKT抑制剂针对特定的基因变异,标志着瘤学药物开发的重要里程碑.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 卡比瓦塞尔蒂布 (TruqapTM) 是一种口服可用的小分子泛AKT抑制剂,由AstraZeneca开发.
- 它适用于各种癌症,包括乳腺癌和前列腺癌.
研究的目的:
- 总结一下capivasertib的发展里程碑.
- 为了突出其首次批准HR阳性,HER2阴性乳腺癌.
主要方法:
- 对临床开发数据的审查.
- 对监管提交和批准流程的分析.
主要成果:
- Capivasertib在2023年11月获得了美国FDA的首次批准.
- 批准适用于HR阳性,HER2阴性局部晚期或转移性乳腺癌中具有特定遗传变异的成年患者.
结论:
- 对Capivasertib的批准代表了针对性癌症治疗的重大进展.
- 其他癌症类型的进一步开发正在进行中,包括前列腺癌.
更多相关视频
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Targeted Cancer Therapies
There are several types of targeted therapies against...